$ cat ./records/gates-foundation-commits-169-million-to-serum-institute-for-r21-m-2022.txt
Gates Foundation Commits $169 Million to Serum Institute for R21/Matrix-M Malaria Vaccine Manufacturing
[RECORD.TXT] · cat --full
The Gates Foundation committed $169 million to the Serum Institute of India to manufacture the R21/Matrix-M malaria vaccine developed by the University of Oxford with Novavax's adjuvant. R21/Matrix-M achieved 75 percent efficacy in Phase III trials across Burkina Faso, Mali, Kenya, and Tanzania — the highest efficacy ever reported for a malaria vaccine. The WHO recommended R21 in October 2023, expanding global malaria vaccine supply from 15 million to nearly 100 million doses annually.
Source: https://www.ox.ac.uk/news/2021-04-23-oxford-malaria-vaccine-results-published-lancet
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Pledges $154 Million to CEPI 100 Days Mission for Pandemic Vaccines in Under 100 Days
Next →
Upside Foods Achieves Unicorn Status in $400 Million Round Backed by Gates
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.